JEFFERSON CITY, Mo. (CN) - Allergan will pay $600 million to settle claims that it pushed Botox for off-label uses. Allergan will pay states and the federal government $225 million to compensate Medicare and Medicaid, plus $350 million in criminal fines and $25 million in forfeiture, Attorney General Chris Koster said.
The company pleaded guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act.
The settlement resolves claims that Allergan promoted Botox for unapproved uses such as headache, pain, overactive bladder and spasticity.
Allergan ran a nationwide campaign to push the drug for off-label uses. It included reimbursements to physicians and other support.
Doctors may prescribe drugs for off-label uses, but drug companies cannot push their drugs for that. Missouri will get $1.6 million from the settlement, Koster said.
Follow @@joeharris_stl
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
Alaska, Hawaiian Airlines April 17, 2024 -
-
Contributor-Test-Post-2024-04-12 April 12, 2024 -
